Cancer drugs: Phase II clinical studies enough for registration.

The KFDA may approve the product registration for anti-cancer drugs only with the phase II clinical study data to speed up the drug development and help cancer patients to get an appropriate treatment utmost timely, admitting the clinical phase II studies enough to identify its efficacy and safety.

Accordingly, the additional indications for any cancer drugs already on the market will be gra...